CD163 and pulmonary hypertension: In our study that included 203 patients (with 71/179 (39.6%) having PASP > 30, 22/179 (12.3%) having PASP > 40, and 14/192 (7.3%) with proven pulmonary hypertension), we could not find any relationship between sCD163 concentrations and lung vascular disease.